MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient With Severe ARDS at ATS Annual Meeting
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient With Severe ARDS at ATS Annual Meeting
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting. These translational and mechanistic insights build on an expanding dataset of clinical activity for patients with severe ARDS.
2024年5月22日，紐約（環球新聞社）——MiNK Therapeutics，Inc.（NASDAQ:INKT），一家臨床階段的生物製藥公司，致力於發現，開發和商業化同種異體，現成的，不變的自然殺傷T細胞治療癌症和其他免疫介導疾病，今天宣佈在美國胸科學會（ATS）年會上公佈agenT-797在嚴重急性呼吸窘迫綜合症（ARDS）複雜病例的臨床數據報告。這些轉化和機制方面的見解是與嚴重ARDS患者的臨床活動不斷擴大的數據集相結合而形成的。
"Consistent with our prior publication of the survival benefit of agenT-797 in severe respiratory distress, the observed improvement in this case further demonstrates the potential of allogeneic iNKT cells in this setting," said Dr. Terese Hammond, University of California Los Angeles. "New therapeutic options, like allogeneic cell therapies, are urgently needed to address the critical unmet need in immune-compromised individuals with respiratory distress. I believe this growing body of data illuminates how iNKTs may have an impactful role in treating acute critical illness and merits further investigation."
“與我們之前的agenT-797在嚴重呼吸窘迫中的生存利益的發表相一致，這種病例的觀察到的改善進一步證明了同種異體iNKT細胞在這種情況下的潛力，”加州大學洛杉磯分校的特雷斯·哈蒙德博士說。“像同種異體細胞療法這樣的新治療選擇，迫切需要解決呼吸窘迫的免疫受損個體的嚴重未滿足需求。我認爲這個不斷增長的數據體系闡明瞭iNKT在治療急性重症上可能具有有影響力的作用，並值得進一步研究。”
Clinical Findings
臨床發現
- Patient: A 26-year-old chronically immunosuppressed patient post-renal transplant contracted COVID-19 and progressed to severe hypoxemic respiratory failure, requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO).
- Treatment: A single dose of 1x10^9 allogeneic iNKT cells (agenT-797) on hospital day 13.
-
Outcomes: Clinical changes showed a rapid decrease in inflammatory cytokines, including IL-18 following agenT-797 administration, consistent with the data observed in the Phase 1 trial of agenT-797 in COVID-19 ARDS (Hammond, T.C., Nat Commun 2024). The patient was extubated on day 37 and discharged home from the hospital on day 60, weaned off hemodialysis and returned to normal activities of daily living (ADLs) within 6 months of dosing.
- 患者：26歲的慢性免疫抑制患者，在腎移植術後感染COVID-19，並發展爲嚴重的低氧性呼吸衰竭，需要靜脈-靜脈體外膜氧合（VV-ECMO）治療。
- 治療：住院第13天單次使用1 x 10^9同種異體iNKT細胞（agenT-797）。
- 結果：與agenT-797的使用相關的臨床改變顯示，炎性細胞因子，包括白細胞介素18，在agenT-797給藥後迅速下降，這與agenT-797在COVID-19ARDS的1期試驗中所觀察到的數據一致（Hammond, T.C.，Nat通訊，）。此患者於第37天拔管，並於第60天從醫院出院，在6個月的用藥中逐漸停止了透析，並恢復了日常生活（ADLs）。漢蒙德，T.C.， 自然通訊 2024）。
The full poster presentation can be found on the Publications page of the MiNK website at https://minktherapeutics.com/publications/.
MiNK網站的出版物頁面上可以找到完整的海報演講稿，網址是https://minktherapeutics.com/publications/.
About MiNK Therapeutics
MiNK Therapeutics簡介
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MiNK Therapeutics是一家臨床生物製藥公司，致力於發現、研發和商業化同種異體不變自然殺傷T細胞（iNKT）療法，以治療癌症和其他免疫介導性疾病。MiNK正在推進一系列原生和下一代工程iNKT計劃，平台旨在爲現成送貨提供可擴展和可重複生產的工具。公司總部位於紐約市。欲了解更多信息，請訪問https://minktherapeutics.com/或關注@MiNK_iNKT。可能對投資者重要的信息將定期發佈在我們的網站和社交媒體渠道上。
Forward Looking Statements
前瞻性聲明
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
本新聞稿包含根據聯邦證券法規定的安全港條款發佈的前瞻性聲明，包括針對agenT-797和iNKT細胞的治療和治癒潛力，作用機制，效力和安全性，中期或前線數據，包括agenT-797的臨床數據，agenT-797的預期好處和臨床開發計劃和時間表等聲明。這些前瞻性聲明受到可能導致實際結果明顯不同的風險和不確定性的影響。MiNK不斷告誡投資者不要過份依賴本新聞稿中包含的前瞻性聲明。這些聲明僅於本新聞稿發佈之日起生效，並且MiNK無義務更新或修訂這些聲明，除非法律規定的程度要求。所有的前瞻性聲明都在其整體上通過這一警示聲明得到了明確的合格。
Investor Contact
投資者聯繫方式
917-362-1370
917-362-1370
Media Contact
媒體聯繫人
781-674-4428
781-674-4428
Source: MiNK Therapeutics
來源：MiNK治療